First-in-human: BCMA CAR-T plus gamma secretase inhibitor in R/R myeloma

Safety and Efficacy of Fully Human BCMA CAR T Cells in Combination with a Gamma Secretase InhibitorПодробнее

Novel combination in MM: BCMA CAR T-cells with a gamma secretase inhibitorПодробнее

Phase I trial evaluating a gamma secretase inhibitor in combination with CAR-T cells in R/R myelomaПодробнее

Phase I study of CART-ddBCMA in R/R multiple myelomaПодробнее

Hitting the BCMA Target in Multiple MyelomaПодробнее

Phase I study of bb21217 CAR-T therapy in R/R myelomaПодробнее

Dr. Green presents on the combined use of Gamma Secretase Inhibitor and CAR T Cells at ASH 2021.Подробнее

Andrew Cowan, MD, discusses the role of human BCMA CAR-T cells in the management of multiple myelomaПодробнее

Phase I CRB-402 Study of the BCMA-Targeted CAR T Cell Therapy bb21217 in Pts w/RR Multiple MyelomaПодробнее

ALLO-715: BCMA allogeneic CAR-T in R/R myelomaПодробнее

CAR T-Cell Therapy for Multiple MyelomaПодробнее

CAR-T therapy in multiple myeloma: research blind spotsПодробнее

FHVH-BCMA-T CAR T-cell therapy shows efficacy in R/R myelomaПодробнее

bb21217: next gen anti-BCMA CAR-T for R/R MMПодробнее

Phase 1 Study PHE885 BCMA-Directed CAR-T Cell Therapy for RRMM | Adam Sperling, MD, PhD | ASCO 2023Подробнее

Phase I/II trial of P-BCMA-101 CAR-T cell therapy in R/R myelomaПодробнее

The future in multiple myeloma: BiTE immunotherapy, CAR-T, and immune checkpoint inhibitorsПодробнее

ide-cel; bb2121, a BCMA-targeted CAR T-cell therapy, in patients with RRMM: Initial KarMMa resultsПодробнее

What is gamma secretase? #myelomaПодробнее